Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 10Squamous Cell Carcinoma of Head and Neck 3Oropharyngeal Neoplasms 3Neoplasm Metastasis 3Uterine Cervical Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Pheochromocytoma 2Paraganglioma 2Ovarian Neoplasms 2Multiple Myeloma 2Mouth Neoplasms 2Melanoma 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Stage III Lung Non-Small Cell Cancer AJCC v7 1Solid Tumor 1Small Cell Lung Carcinoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1

Interventions

Rituximab 40Cyclophosphamide 36Prednisone 24Doxorubicin 23Magnetic Resonance Spectroscopy 20Vincristine 19Gemcitabine 18Specimen Handling 17Lenalidomide 17Biopsy 15Oxaliplatin 14polatuzumab vedotin 13obinutuzumab 11glofitamab 11ibrutinib 10fludarabine 8Etoposide 8Dexamethasone 8CT-P10 8prednylidene 7deltacortene 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7venetoclax 6tafasitamab 6pembrolizumab 6Prednisolone 6fludarabine phosphate 5acalabrutinib 5R-CHOP protocol 5Cyclosporine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × Fluorodeoxyglucose F18 × 90 days × Clear all
NCT07097363 2026-04-23

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

University of Washington

Phase 2 Recruiting
18 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡